TYR and melanoma: Misfolded ERAD substrates are usually sent to degradation via a glyco-dependent ubiquitin–proteasome pathway, so we next tested whether proteasome or mannosidase inhibitors would stop the EDEM2-induced degradation of ST-TYR in A375 melanoma cells.